Body fat composition as biomarker for clinical outcomes and treatment tolerance in high-risk prostate cancer.
Anurag Saraf(Dana-Farber Brigham Cancer Center), Paul L. Nguyen(Beth Israel Deaconess Medical Center), Benjamin H. Kann(Brigham and Women's Hospital), Jack M. Qian(South Shore Hospital), Danielle S. Bitterman(Brigham and Women's Hospital), Vinayak Muralidhar(Kaiser Permanente), Raymond H. Mak(Twitter (United States)), Anthony V. D’Amico(Brigham and Women's Hospital), Subha Perni(Dana-Farber Brigham Cancer Center), Christian V Gurthier(Brigham and Women's Hospital), Hugo J.W.L. Aerts(Harvard University), Zhongyi Zhang(Intel (United States)), Jakob Weiß(University of Freiburg)
Cited by 0
Related Papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Artificial intelligence in radiation oncology
|Nature Reviews Clinical Oncology|2020|399
The TRIPOD-LLM reporting guideline for studies using large language models
|Nature Medicine|2025|340